Skip to Content

Novartis AG Registered Shares NOVN

Morningstar Rating
CHF 89.50 −0.50 (0.56%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

NOVN is trading at a 1% discount.
Price
CHF 87.36
Fair Value
CHF 69.00
Uncertainty
Medium
1-Star Price
CHF 235.90
5-Star Price
CHF 75.70
Economic Moat
Lpvn
Capital Allocation
Wdwsnch

Bulls Say, Bears Say

Bulls

Novartis' solid late-stage pipeline should propel long-term growth. The company should launch several new drugs during the next several years in critical therapeutic areas such as rare diseases and oncology.

Bears

The patent loss on multiple sclerosis drug Gilenya creates a significant drag on sales in 2023-24 as generic competition increases.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NOVN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
CHF 90.00
Day Range
CHF 89.1090.30
52-Week Range
CHF 79.2194.52
Bid/Ask
CHF 0.00 / CHF 0.00
Market Cap
CHF 182.62 Bil
Volume/Avg
3.2 Mil / 3.3 Mil

Key Statistics

Price/Earnings (Normalized)
14.58
Price/Sales
4.18
Dividend Yield (Trailing)
3.78%
Dividend Yield (Forward)
3.78%
Total Yield
3.67%

Company Profile

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
76,057

Competitors

Valuation

Metric
NOVN
GSK
JNJ
Price/Earnings (Normalized)
14.5810.6614.07
Price/Book Value
5.084.805.14
Price/Sales
4.182.244.12
Price/Cash Flow
13.8810.6818.53
Price/Earnings
NOVN
GSK
JNJ

Financial Strength

Metric
NOVN
GSK
JNJ
Quick Ratio
0.880.590.91
Current Ratio
1.160.881.16
Interest Coverage
10.949.3018.88
Quick Ratio
NOVN
GSK
JNJ

Profitability

Metric
NOVN
GSK
JNJ
Return on Assets (Normalized)
13.39%10.54%13.98%
Return on Equity (Normalized)
31.09%50.48%35.02%
Return on Invested Capital (Normalized)
19.67%21.33%22.24%
Return on Assets
NOVN
GSK
JNJ
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoFrtzkckjdbPrlmc$697.4 Bil
JNJ
Johnson & JohnsonZknfzsffyRssn$353.8 Bil
MRK
Merck & Co IncZftdkxclNrnx$332.3 Bil
ABBV
AbbVie IncCprvdrsbZxyc$282.6 Bil
AZN
AstraZeneca PLC ADRCfpxgnvgsGjsh$232.3 Bil
NVS
Novartis AG ADRGqxcgxcqNqxyz$200.1 Bil
RHHBY
Roche Holding AG ADRPympqxpkkdJczv$195.3 Bil
AMGN
Amgen IncKmbzyjvfcDwwlt$144.5 Bil
PFE
Pfizer IncVxdbfqqnCmgx$143.8 Bil
SNY
Sanofi SA ADRShwyyjjWzrh$122.2 Bil

Sponsor Center